HBIO

Over the past six months, Harvard Bioscience's stock price has been impacted by several events. A reverse stock split on March 6, 2026, led to a decline in the stock price. The announcement of Fourth Quarter and Full-Year 2025 financial results on March 12, 2026, resulted in a stock decline, followed by a subsequent increase over the next 55 days. HBIO participated in the KeyBanc Virtual Healthcare Forum on March 17, 2026, and has scheduled investor conferences. Equity grants were awarded to the CFO and CEO in April 2026. A Schedule 13D filing on March 23, 2026, reported BroadOak's stake in HBIO. Nasdaq granted an extension to regain compliance with the minimum bid price requirement. Overall, the stock has experienced a decline over the past six months.